Johns Hopkins spin-out Gemstone Biotherapeutics secures $2.45m seed round for wound treatments.
Gemstone Biotherapeutics, a spin-out of Johns Hopkins University (JHU), has raised $2.45m in seed round backing.
The round was led by investor Gamma 3, which provided $1.6m, and was joined in participation by an unnamed life sciences fund.
The company is commercialising a biosynthetic scaffold which can be used to treat wounds. In animal tests, the technology has shown in can help regenerate skin and prevent scarring from burn wounds. The funding will be used to further test the technology, and to pursue clinical trials.
George Davis, Gemstone’s CEO, said: “The potential to revolutionise the wound care industry is incredibly exciting for our investors, our industry and, most significantly, for patients with chronic and acute wounds. This latest round of funding will enable us to more aggressively pursue major regulatory and clinical milestones.”
This article is part of Global University Venturing’s free-to-access month. Subscriptions taken out this month will be 25% off.
